Research Radartracking 85 published studies · 25 human · 14 clinical trials · 14 cancer pages · updated Jun 2026Open the Research Map →

Uterine Leiomyosarcoma

Auto-discovered from research; not yet curated.

Auto-added · review pending
Educational only: This page is not medical advice. Coordinate decisions with your oncology team.

OncoForge editorial · How we review →

AI extractedhuman reviewedsources checkedretractions suppressed

Evidence at a glanceHuman · observationalReported positive
1 published studies that name Uterine Leiomyosarcoma1 human studies approved & graded (trial, observational, or meta-analysis)146 human clinical studies in the Uterine Leiomyosarcoma corpus757 source documents in the Uterine Leiomyosarcoma corpus
Why this grade?

Human · observational — Human observational evidence only — no trials.

Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.

What the guidelines say

NCI PDQESMONCCNASCO

We link the authoritative guidelines rather than reproduce them. Below, the treatments on this page are split by whether they’re guideline-backed standard of care or studied but not standard — so you can tell the established options from the experimental ones.

Studied, not standard · investigational
  • Trastuzumab Deruxtecan
  • Trastuzumab-Deruxtecan (T-Dxd)

Read the guidelines

Cancer-specific deep links aren’t curated yet — these search the authoritative sources for Uterine Leiomyosarcoma.

Treatment map: Uterine Leiomyosarcoma

Open as a full page →

Standard care plus every compound studied in the literature (each cited) and graded by evidence, organized by clinical readiness. A category, not a verdict that anything works — confirm anything here with your oncology team.

2
Interventions
0
Standard of care
2
Tested in people
0
Lab / animal
0
Named in lit.
1
Classes
Standard of care (0) Guideline option (0) Tested in people (2) Lab / animal only (0) Named in the literature (0)

Tested in people, by trial phase: phase not reported ×2

Investigational & adjunct compounds — detail (2)

"Tested in people" rows show the highest trial phase found in that compound's cited human studies (Phase I–IV; "phase not reported" = a human study with no phase tag). "Studied" = named in the cited literature for this cancer. "FDA ✓" = FDA-approved for this cancer; "off-label" = an FDA-approved drug used outside its approved indications (per openFDA). Not a claim that anything works.

Reported figures

Get cited updates on Uterine Leiomyosarcoma
A monthly email when the research changes — $10/mo. Manage follows
Follow Uterine Leiomyosarcoma

What supports this page

The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.

Guideline
83
Meta-analysis
110
Systematic review
24
Randomized trial
1
Clinical trial
3
Observational
2
Case report
67
Review
466
Preclinical
0
Other
1

Living document — last change June 12, 2026: New cancer type added.

Overview

Uterine Leiomyosarcoma is tracked here from the published studies that mention it. This page shows the research evidence collected so far — it is not a curated clinical overview.

Medicines & supplements studied for Uterine Leiomyosarcoma

PubMedFDAClinicalTrials.gov

Every drug, supplement, and other agent the published studies cover for Uterine Leiomyosarcoma, ranked by how strong the evidence is — what studies report, not a recommendation. Tap any to see its full profile.

Medicines · 2

Trastuzumab DeruxtecanHuman · observationalReported positive1 human

Human observational evidence only — no trials.

Largest credible effect: median PFS 5.4 mo [0.8–9.8], n=10 PMID 39639215 · effect sizes 1–5 across 3 studies

Most authoritative study: Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies

Based on a single study.
Targeted therapy1 studyFull profile →
Trastuzumab-Deruxtecan (T-Dxd)Human · observationalReported positive1 human

Human observational evidence only — no trials.

Largest credible effect: median PFS 5.4 mo [0.8–9.8], n=10 PMID 39639215 · effect sizes 1–5 across 3 studies

Most authoritative study: Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies

Based on a single study.
Targeted therapy1 studyFull profile →

What recent studies report in Uterine Leiomyosarcoma

These are reviewed studies whose abstracts concern Uterine Leiomyosarcoma. Each describes only what that study reported. This is not a claim by OncoForge that any compound helps or harms Uterine Leiomyosarcoma. Most are early lab, animal, or small human studies, and findings often conflict.

1 study1 human

Tracking 1 published study of Uterine Leiomyosarcoma: 1 in humans.

Reported direction across studies: 1 positive.

These counts summarize what the studies reported; they are not a measure of whether anything works for Uterine Leiomyosarcoma.

Compounds with studies mentioning Uterine Leiomyosarcoma

Trastuzumab deruxtecan t dxd (1)Trastuzumab deruxtecan (1)
Human · observationalReported positiveLimited evidenceTier 3 · early humann = 10

Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies

BMC cancer · Dec 2024 · retrospective cohort

Trastuzumab-deruxtecan-t-dxdTrastuzumab-deruxtecanendometrial neoplasmsovarian neoplasmscervical neoplasmsuterine carcinosarcomauterine leiomyosarcomauterine serous carcinomaovarian carcinosarcomahigh-grade serous ovarian carcinomamucinous ovarian carcinomasquamous cervical carcinoma

This retrospective single-center study identified 10 patients with HER2-expressing (IHC 2+/3+) recurrent or metastatic gynecological cancers who received trastuzumab deruxtecan (5.4 mg/kg IV every 3 weeks). The cohort had a median progression-free survival of 5.4 months (95% CI 0.8-9.8). Five patients had a partial response, one had stable disease at 12 weeks, and four had disease progression at initial assessment. Clinical benefit was observed mainly in tumors with HER2 IHC 3+.

Reported effects: median PFS 5.4 mo [0.8–9.8], n=10 · partial responses 5, n=10 · +2 more

Key findings
  • 10 patients with recurrent/metastatic HER2-expressing gynecological malignancies were treated with T-DXd.
  • Histologies included uterine neoplasms (n=5), cervical squamous carcinoma (n=1) and ovarian cancers (n=4).
  • Median age was 65.4 years (25th-75th percentile, 58.1-75.2 years).
  • HER2 by IHC: 5 patients were 3+ and 5 patients were 2+.
  • Median number of prior therapy lines was 4 (range 2-6); 2 uterine serous carcinoma patients were pretreated with trastuzumab and 4 patients had prior immunotherapy.
  • Dose: T-DXd 5.4 mg/kg IV every 3 weeks until progression/toxicity.
  • Median progression-free survival (PFS) in the cohort was 5.4 months (95% CI 0.8-9.8 months).
  • Responses: 5 patients had partial response (including 2 previously treated with trastuzumab), 1 patient had stable disease at 12 weeks, 4 patients had disease progression at initial assessment.
  • Most patients who derived clinical benefit had HER2 IHC 3+ expression.
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract; Potential selection and reporting bias inherent to retrospective series.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Browse all studies mentioning Uterine Leiomyosarcoma →

Where the evidence is

What has been studied, and how strong it is, by topic. A dashed cell means no studies were found for that combination — a gap, not evidence of no effect. Open a row to see its studies.

CompoundHuman evidenceMechanismSafetyTrial
Trastuzumab Deruxtecan1———
Trastuzumab-Deruxtecan (T-Dxd)1———

Compounds with reported-positive results in Uterine Leiomyosarcoma

Where at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.

Human evidence

Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Cited positive studies (1)
Trastuzumab Deruxtecan1 positive1 human
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Cited positive studies (1)

Evidence at a glance: compounds studied in Uterine Leiomyosarcoma

A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.

Trastuzumab DeruxtecanHuman · observationalReported positive1 human

Human observational evidence only — no trials.

Largest credible effect: median PFS 5.4 mo [0.8–9.8], n=10 PMID 39639215 · effect sizes 1–5 across 3 studies

Most authoritative study: Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies

Based on a single study.
Trastuzumab-Deruxtecan (T-Dxd)Human · observationalReported positive1 human

Human observational evidence only — no trials.

Largest credible effect: median PFS 5.4 mo [0.8–9.8], n=10 PMID 39639215 · effect sizes 1–5 across 3 studies

Most authoritative study: Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies

Based on a single study.

Clinical trials in Uterine Leiomyosarcoma

Loading current trials from ClinicalTrials.gov… Search ClinicalTrials.gov →

Getting care & support

Nonprofit / Gov

Practical, vetted help for Uterine Leiomyosarcoma — advocacy, paying for treatment, second opinions, and caregivers.

If you’re struggling emotionally, you don’t have to wait.

Advocacy & community

No dedicated organization for this specific cancer is curated yet — these general organizations can help in the meantime.

Financial help

  • PAN Foundation ↗ — Copay assistance funds by diagnosis (funds open and close as money allows). · status changes often — check the fund’s site
  • HealthWell Foundation ↗ — Copay and premium assistance funds by disease. · status changes often — check the fund’s site
  • CancerCare — financial assistance ↗ — Limited grants plus free financial counseling. · status changes often — check the fund’s site
  • Family Reach ↗ — Help with everyday living costs (rent, transport, food) during treatment. · status changes often — check the fund’s site
  • NeedyMeds ↗ — Searchable directory of drug patient-assistance and discount programs. · status changes often — check the fund’s site
What you’ll typically need to apply
  • Your diagnosis and, if you have it, the specific drug/treatment name (from your care team).
  • Insurance details — your member ID card, or a note that you're uninsured (some funds require active insurance, some don't).
  • Proof of income and household size (recent pay stubs, a tax return, or a benefits letter) — most funds are income-based.
  • Your prescriber's contact information; some programs need the clinic to submit part of the application.
  • Apply early and re-check: funds open and close as money is available, so a closed fund may reopen.

General guidance — each program sets its own eligibility. Confirm requirements on the program’s site.

Help paying for the medicines on this page

Second opinions

Caregiver support

We list only non-profit and government resources — never product sellers — and take no affiliate fees. If a link is broken or a resource doesn't meet that bar, tell us.

Heading to an appointment? Get a printable one-page summary — studied compounds, open trials, interactions, and questions to ask.
Bring this to your appointment →